{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:41:08Z","timestamp":1792442468260,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"DOI":"10.1038\/s41401-026-01901-x","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:03:05Z","timestamp":1792396985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MMP14-mediated proteolytic cleavage of LAMC2 domain III fragment drives osimertinib resistance in EGFR-mutant non-small cell lung cancer"],"prefix":"10.1038","author":[{"given":"Cong-hua","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-da","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai-juan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-yue","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"1901_CR1","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","volume":"94","author":"N Duma","year":"2019","unstructured":"Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94:1623\u201340.","journal-title":"Mayo Clin Proc"},{"key":"1901_CR2","first-page":"2892","volume":"5","author":"A Midha","year":"2015","unstructured":"Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5:2892\u2013911.","journal-title":"Am J Cancer Res"},{"key":"1901_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113\u201325.","journal-title":"N Engl J Med"},{"key":"1901_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41\u201350.","journal-title":"N Engl J Med"},{"key":"1901_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.lungcan.2020.07.014","volume":"147","author":"S Schmid","year":"2020","unstructured":"Schmid S, Li JJN, Leighl NB. Mechanisms of osimertinib resistance and emerging treatment options. Lung Cancer. 2020;147:123\u20139.","journal-title":"Lung Cancer"},{"key":"1901_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102557","volume":"116","author":"Z Zalaquett","year":"2023","unstructured":"Zalaquett Z, Catherine Rita Hachem M, Kassis Y, Hachem S, Eid R, Raphael Kourie H, et al. Acquired resistance mechanisms to osimertinib: the constant battle. Cancer Treat Rev. 2023;116:102557.","journal-title":"Cancer Treat Rev"},{"key":"1901_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216762","volume":"588","author":"R Han","year":"2024","unstructured":"Han R, Lin C, Lu C, Wang Y, Kang J, Hu C, et al. Sialyltransferase ST3GAL4 confers osimertinib resistance and offers strategies to overcome resistance in non-small cell lung cancer. Cancer Lett. 2024;588:216762.","journal-title":"Cancer Lett"},{"key":"1901_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08074-0","volume":"10","author":"H Taniguchi","year":"2019","unstructured":"Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, et al. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nat Commun. 2019;10:259.","journal-title":"Nat Commun"},{"key":"1901_CR9","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725\u201337.","journal-title":"Br J Cancer"},{"key":"1901_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35961-y","volume":"14","author":"J Chmielecki","year":"2023","unstructured":"Chmielecki J, Gray JE, Cheng Y, Ohe Y, Imamura F, Cho BC, et al. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nat Commun. 2023;14:1070.","journal-title":"Nat Commun"},{"key":"1901_CR11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9:274.","journal-title":"Signal Transduct Target Ther"},{"key":"1901_CR12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","volume":"15","author":"KC Valkenburg","year":"2018","unstructured":"Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018;15:366\u201381.","journal-title":"Nat Rev Clin Oncol"},{"key":"1901_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020;11:5120.","journal-title":"Nat Commun"},{"key":"1901_CR14","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10585-019-09966-1","volume":"36","author":"JA Eble","year":"2019","unstructured":"Eble JA, Niland S. The extracellular matrix in tumor progression and metastasis. Clin Exp Metastasis. 2019;36:171\u201398.","journal-title":"Clin Exp Metastasis"},{"key":"1901_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.matbio.2015.06.003","volume":"49","author":"A Naba","year":"2016","unstructured":"Naba A, Clauser KR, Ding H, Whittaker CA, Carr SA, Hynes RO. The extracellular matrix: tools and insights for the \u201comics\u201d era. Matrix Biol. 2016;49:10\u201324.","journal-title":"Matrix Biol"},{"key":"1901_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s42003-022-03111-7","volume":"5","author":"L Li","year":"2022","unstructured":"Li L, Li Z, Lu C, Li J, Zhang K, Lin C, et al. Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin alpha5\/FAK signaling. Commun Biol. 2022;5:155.","journal-title":"Commun Biol"},{"key":"1901_CR17","doi-asserted-by":"publisher","first-page":"e009165","DOI":"10.1136\/jitc-2024-009165","volume":"12","author":"C Lu","year":"2024","unstructured":"Lu C, Gao Z, Wu D, Zheng J, Hu C, Huang D, et al. Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect. J Immunother Cancer. 2024;12:e009165.","journal-title":"J Immunother Cancer"},{"key":"1901_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.canlet.2019.03.027","volume":"452","author":"L Li","year":"2019","unstructured":"Li L, Wang Y, Jiao L, Lin C, Lu C, Zhang K, et al. Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer. Cancer Lett. 2019;452:191\u2013202.","journal-title":"Cancer Lett"},{"key":"1901_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11153-5","volume":"10","author":"XD Wang","year":"2019","unstructured":"Wang XD, Hu R, Ding Q, Savage TK, Huffman KE, Williams N, et al. Subtype-specific secretomic characterization of pulmonary neuroendocrine tumor cells. Nat Commun. 2019;10:3201.","journal-title":"Nat Commun"},{"key":"1901_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH, et al. Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021;12:1088.","journal-title":"Nat Commun"},{"key":"1901_CR21","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1083\/jcb.148.3.615","volume":"148","author":"N Koshikawa","year":"2000","unstructured":"Koshikawa N, Giannelli G, Cirulli V, Miyazaki K, Quaranta V. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol. 2000;148:615\u201324.","journal-title":"J Cell Biol"},{"key":"1901_CR22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1083\/jcb.200208145","volume":"161","author":"S Schenk","year":"2003","unstructured":"Schenk S, Hintermann E, Bilban M, Koshikawa N, Hojilla C, Khokha R, et al. Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution. J Cell Biol. 2003;161:197\u2013209.","journal-title":"J Cell Biol"},{"key":"1901_CR23","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1158\/0008-5472.CAN-11-4149","volume":"72","author":"AG Remacle","year":"2012","unstructured":"Remacle AG, Golubkov VS, Shiryaev SA, Dahl R, Stebbins JL, Chernov AV, et al. Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth. Cancer Res. 2012;72:2339\u201349.","journal-title":"Cancer Res"},{"key":"1901_CR24","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.21037\/atm-21-4507","volume":"9","author":"M Liu","year":"2021","unstructured":"Liu M, Cai R, Wang T, Yang X, Wang M, Kuang Z, et al. LAMC2 promotes the proliferation of cancer cells and induces infiltration of macrophages in non-small cell lung cancer. Ann Transl Med. 2021;9:1392.","journal-title":"Ann Transl Med"},{"key":"1901_CR25","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/cdd.2014.228","volume":"22","author":"YW Moon","year":"2015","unstructured":"Moon YW, Rao G, Kim JJ, Shim HS, Park KS, An SS, et al. LAMC2 enhances the metastatic potential of lung adenocarcinoma. Cell Death Differ. 2015;22:1341\u201352.","journal-title":"Cell Death Differ"},{"key":"1901_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.pharmthera.2012.02.002","volume":"134","author":"JK Burgess","year":"2012","unstructured":"Burgess JK, Weckmann M. Matrikines and the lungs. Pharmacol Ther. 2012;134:317\u201337.","journal-title":"Pharmacol Ther"},{"key":"1901_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35780","volume":"131","author":"D Reinhorn","year":"2025","unstructured":"Reinhorn D, Moskovitz M, Tap WD, Li BT. Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies. Cancer. 2025;131:e35780.","journal-title":"Cancer"},{"key":"1901_CR28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.celrep.2019.09.004","volume":"29","author":"T Bui","year":"2019","unstructured":"Bui T, Rennhack J, Mok S, Ling C, Perez M, Roccamo J, et al. Functional redundancy between \u03b21 and \u03b23 integrin in activating the IR\/Akt\/mTORC1 signaling axis to promote ErbB2-driven breast cancer. Cell Rep. 2019;29:589\u2013602.e6.","journal-title":"Cell Rep"},{"key":"1901_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/ijms22010238","volume":"22","author":"S Niland","year":"2020","unstructured":"Niland S, Eble JA. Hold on or cut? Integrin- and MMP-mediated cell-matrix interactions in the tumor microenvironment. Int J Mol Sci. 2020;22:238.","journal-title":"Int J Mol Sci"},{"key":"1901_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0304-3835(02)00699-7","volume":"194","author":"M Seiki","year":"2003","unstructured":"Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett. 2003;194:1\u201311.","journal-title":"Cancer Lett"},{"key":"1901_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1878-0261.12155","volume":"12","author":"S Sigismund","year":"2018","unstructured":"Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12:3\u201320.","journal-title":"Mol Oncol"},{"key":"1901_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.tcb.2013.11.002","volume":"24","author":"A Tomas","year":"2014","unstructured":"Tomas A, Futter CE, Eden ER. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol. 2014;24:26\u201334.","journal-title":"Trends Cell Biol"},{"key":"1901_CR33","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41586-021-04057-2","volume":"599","author":"X Sun","year":"2021","unstructured":"Sun X, Wu B, Chiang HC, Deng H, Zhang X, Xiong W, et al. Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion. Nature. 2021;599:673\u20138.","journal-title":"Nature"},{"key":"1901_CR34","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/JCI45817","volume":"122","author":"H Salmon","year":"2012","unstructured":"Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A, et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest. 2012;122:899\u2013910.","journal-title":"J Clin Invest."},{"key":"1901_CR35","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to the exclusion of T cells. Nature. 2018;554:544\u20138.","journal-title":"Nature"},{"key":"1901_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.neo.2016.11.005","volume":"19","author":"M Stawowczyk","year":"2017","unstructured":"Stawowczyk M, Wellenstein MD, Lee SB, Yomtoubian S, Durrans A, Choi H, et al. Matrix metalloproteinase 14 promotes lung cancer by cleaving the heparin-binding EGF-like growth factor. Neoplasia. 2017;19:55\u201364.","journal-title":"Neoplasia"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01901-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01901-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01901-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:02:56Z","timestamp":1792440176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01901-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":36,"alternative-id":["1901"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01901-x","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}